key: cord-0807329-e6g4ink8
authors: Park, Jun-Guy; Oladunni, Fatai S.; Rohaim, Mohammed A.; Whittingham-Dowd, Jayde; Tollitt, James; Hodges, Matthew D.J.; Fathallah, Nadin; Assas, Muhsref Bakri; Alhazmi, Wafaa; Almilaibary, Abdullah; Iqbal, Munir; Chang, Pengxiang; Escalona, Renee; Shivanna, Vinay; Torrelles, Jordi B.; Worthington, John J.; Jackson-Jones, Lucy H.; Martinez-Sobrido, Luis; Munir, Muhammad
title: Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2
date: 2021-08-04
journal: iScience
DOI: 10.1016/j.isci.2021.102941
sha: bdf5dd958b9645145a805909ee55d221cbf4b913
doc_id: 807329
cord_uid: e6g4ink8

Global deployment of an effective and safe vaccine is necessary to curtail the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we evaluated a Newcastle disease virus (NDV)-based vectored-vaccine in mice and hamsters for its immunogenicity, safety and protective efficacy against SARS-CoV-2. Intranasal administration of recombinant (r)NDV-S vaccine expressing spike (S) protein of SARS-CoV-2 to mice induced high levels of SARS-CoV-2-specific neutralizing immunoglobulin A (IgA) and IgG2a antibodies and T cell-mediated immunity. Hamsters immunised with two doses of vaccine showed complete protection from lung infection, inflammation, and pathological lesions following SARS-CoV-2 challenge. Importantly, administration of two doses of intranasal rNDV-S vaccine significantly reduced the SARS-CoV-2 shedding in nasal turbinate and lungs in hamsters. Collectively, intranasal vaccination has the potential to control infection at the site of inoculation, which should prevent both clinical disease and virus transmission to halt the spread of the COVID-19 pandemic.

Coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in a seafood market in Wuhan, China We have recently developed an NDV-based SARS-CoV-2 vaccine encoding a human 106 codon optimized full length wild type spike (S) protein of SARS-CoV-2 (rNDV-S) using a 107 reverse genetic approach (Rohaim and Munir, 2020) . The rNDV-S successfully replicated 108 in chicken embryonated eggs and cultured cells to levels comparable to the recombinant 109 saline (PBS). The rNDV-WT and one rNDV-S group of mice received a booster dose of 138 10 6 PFU of rNDV-WT or rNDV-S, respectively, a week later, while other groups were 139 mock-boosted ( Figure 1a ). All animals were euthanized on day 19 post-vaccination for 140 safety assessment, as well as to assess pathological and immunological responses. Mice 141 were monitored daily for weight loss, health status, and feed intake. Initial starting weights 142 did not significantly differ in any experimental group prior to treatment (Figures 1b), and  143 there was no significant alteration in the percentage of basal weight of mice in groups 144 immunised with rNDV-S and the control mock-vaccinated group across the time course 145 of the experiment (Figure 1b ). The first dose of rNDV-S induced a small but significant 146 reduction in basal weight at 2-and 3-days post-vaccination (DPV), but weights returned 147

to comparable levels to mock immunised mice on the following day and for the rest of the 148 time course (Figure 1b) . A reduction in weight was also seen at 14 and 15 DPV in the 149 rNDV-S (prime + boost) group, but weights also quickly returned to mock levels for the 150 rest of the study. Analysis of daily chow intake revealed no significant differences in daily 151 chow consumption among groups ( Figure S1a ). Mice were scored daily assessing 152 movement, coat, temperature, eyes, and signs of hunching on a 14-point scale. No 153 adverse clinical disease signs were observed with an indicated daily score of "0" in the 154 duration of experiments. Following the end of the experiment at day 19 post-vaccination, 155 the gross and histopathological assessment of the right lung lobe showed no significant 156 lesions in any of the treated groups (Figures S1b and Figure 1c) . Additionally, to confirm the spleen of rNDV-WT immunised animals as compared to the mock vehicle control, and 207 although no significant increase was seen in the rNDV-S prime immunised group, a 208 similar but non-significant trend in DC levels was seen in murine spleen after prime + 209 boost rNDV-S immunisation ( Figure S2b ). Despite no significant morphological changes 210 in the cellular architecture in the lung (Figures 1c) , we did observe a significant increase 211 in the cellularity of the lung in the rNDV-S (prime + boost) immunized group, as compared 212 to all other experimental groups studied ( Figure S2c ). However, when we further 213 examined the myeloid immune subsets, we did not observe significant differences in 214 neutrophils, Ly6C-monocyte/macrophages, alveolar macrophages, and eosinophils as 215 To investigate further whether a local inflammatory response occurred following intra-221 nasal vaccination, we assessed the immune response within the pleural cavity. Figures S3g-k) . However, although not significant, a trend for higher amounts of 226 F4/80 hi MHCII lo pleural cells was observed in rNDV-S prime + boost group ( Figure S3f) . 227

Collectively, these data suggest that there is no lasting abhorrent myeloid inflammatory 228 response generated at the site of vaccination or systemically following intranasal delivery 229 J o u r n a l P r e -p r o o f T cell subpopulations producing IL-17 or TNFα, a significant increase in CD4+ T cell IFNγ + 253 (6.4-fold) was observed also in the rNDV-S boosted group as compared to the mock-254 vaccinated group (Figures 3d and 3e) . Collectively, these data indicate no 255 hyperinflammation but both a systemic and local IFNγ T-cell cytokine response to viral 256 antigen following intranasal vaccination with rNDV-S. 257 258 Intranasal vaccination with rNDV-S drives NAb responses specifically targeting 259

Fat associated lymphoid clusters (FALCs) are sites of local Ab production within the 261 pericardium and mediastinum, known for their early response to intranasal challenge 262 had class switched and is consistent with the T cell derived IFNγ + detected upon re-281 stimulation, driving a switch to IgA and/or IgG2a (Figures 4c and 4d) . We next determined 282 the number of B cells present within the pleural lavage fluid and digested pericardium and 283 did not observe significant differences in the numbers of B1a, B1b, or B2 cells present 284 within the pleural lavage fluid or pericardium when comparing rNDV-S boosted to mock 285 control mice ( Figure S6 ). Furthermore, we also did not detect a significant increase in 286 

After establishing the basis of immunological and safety profiles in mice, we next 294 attempted to evaluate the safety of intranasal rNDV-S vaccination in golden Syrian 295 hamsters, which have the advantage of being susceptible to SARS-CoV-2 infection. A 296 total of n=8 hamsters in each group were mock (PBS)-vaccinated or vaccinated with 1 x 297 (boosted, Figure 5b ). Body weight was measured daily for 14 (prime) or 28 (boosted) 299 DPV. Prime vaccination with rNDV-S resulted in no apparent clinical disease except slight 300 (<5%) body weight loss at 5 DPV (Figure 5c ), and no mortality (Figure 5d ). Boosted 301 vaccination also induced less than 10% of body weight loss by 5 DPV (Figure 5e ) with all 302 the animals surviving rNDV-S vaccination (Figure 5f ). Vaccination with rNDV-WT resulted 303 in body weight loss only one day after vaccination in either the prime or boosted 304 vaccinated hamsters (Figures 5c and 5e ). These results demonstrate that vaccination of 305 golden Syrian hamsters with 1 x 10 6 PFU of rNDV-S is safe without lasting significant 306 changes in body weight, with all the animals surviving intranasal rNDV-S vaccination. 307 308

Serum samples collected at 0, 14, and 28 DPV from experimental hamsters were 

Due to the high transmissibility of SARS-CoV-2 and lack of considerable pre-existing 393 immunity, the COVID-19 pandemic is posing significant health challenges particularly 394 in the elderly and those with existing co-morbidities ( replication was detected in nasal turbinate and lungs at 2dpi, animals cleared the challenge virus at 4dpi. Clearance of virus in the respiratory tract is plausible, however, it 416 may merely be just below the detection limit of the assay and thus requires future 417 transmission studies which are beyond the scope of this study. The intranasal route for 418 immunization is advantageous in comparison to traditional routes 419 (i.e., intramuscular) mainly due to its ability to elicit immunity at the local mucosal level 420 

The authors declare no competing interests. 565

One or more of the authors of this paper self-identifies as an underrepresented ethnic 567 minority in science. One or more of the authors of this paper received support from a 568 program designed to increase minority representation in science. While citing references 569 scientifically relevant for this work, we also actively worked to promote gender balance in 570 our reference list. All requests for resources and reagents should be directed to and will be fulfilled by the 698 Lead Contact, Muhammad Munir, PhD (muhammad.munir@lancaster.ac.uk). This 699 includes selective antibodies, viruses, serum and proteins. All reagents will be made 700 available on request after completion of a Materials Transfer Agreement. 701 702

This study did not generate/analyse any datasets/code. 704

Supplementary information is available for this paper. Assay System (Promega). Specifically, 25 μl of substrate in NanoGlo buffer was mixed 860 with 25 μl cell lysate in black flat bottom plates and incubated for 5 min at RT. NanoLuc 861 luciferase activity was measured using Glowmax Navigator luminometer (Promega), 862 using 0.1s integration time. Relative luminescence units (RLU) obtained were normalized 863 to those derived from cells infected with SARS-CoV-2 pseudovirus in the absence of Abs. 864

The half maximal neutralizing concentration (NC50) for sera was determined using 4-865 parameter nonlinear regression curve fit to raw infectivity data measured as relative light 866 units, or as the percentage of infected cells (GraphPad Prism). 867

The day before infection, Vero-E6 cells were seeded at 1×10 4 cells/well into 96-well plates 870 and incubated at 37°C in a 5% CO2 incubator overnight. Mice sera samples were heat 871 protein (1 µg/ml). Viral neutralization was evaluated and quantified using ELISPOT, and 896 a sigmoidal dose-response, non-linear regression curve was generated using GraphPad 897 from the nasal turbinate or lung homogenates from SARS- Spleens were removed from mice and disaggregated through a 100 µm sieve. 918

Pericardium was digested using 1mg/ml Collagenase D (Roche) in a shaking heat block 919 at 37°C, digestion was stopped after 35mins by addition of 5mM EDTA (Fisher) followed 920 by passing through a 100µm cell strainer. Pleural exudate cells (PLEC) were isolated via 921 lavage of the pleural cavity with 10ml of ice cold dPBS (Sigma). Left lung lobes were 922 excised and finely diced using scissors prior to digestion in 2 ml lung digest medium (PBS 923 (Sigma), 0.1mg/ml Liberase TM (Roche), 50 µg/ml DNAse I (Roche)) for 30 min in a 924

shaking incubator at 37°C. Digestion was stopped after 30mins by adding 5mM EDTA 925 In the hamster studies, lungs were collected at 2-and 4-DPI from mock-and SARS-CoV-948 2-challenged golden Syrian hamsters. Lung samples were photographed to show gross 949 lesions on both the dorsal and ventral views. Images were used for macroscopic 950 pathology scoring analysis by measuring the distributions of pathological lesions, 951 including consolidation, congestion, and pneumonic lesions using NIH ImageJ software. 952

The area of pathological lesions was converted into percent of the total lung surface area. 953

Half of the hamster lungs fixed with 10% neutral buffer formalin (NBF) were embedded in 954 paraffin blocks, and sectioned (5 µm). Sections were stained with H&E and evaluated 955 under light microscopy in a blinded manner by a board-certified veterinary pathologist at 956

Texas Biomedical Research Institute. The average inflammation scores were graded 957 based on percent of inflamed lung area: grade 0 = no histopathological lesions observed, 958 grade 1 = minimal (< 10%), grade 2 = mild (10 to 25%), grade 3 = moderate (25 to 50%), 959 grade 4 = marked (50 to 75%), and grade 5 = severe (> 75%). And the neutrophil 960 infiltration scores were graded base on lesion severity as follows: grade 0 = no lesions 961 observed, grade 1 = <10 cells, grade 2 = <25 cells, grade 3 = <50 cells, grade 4 = >100 962 cells, and grade 5 = Too numerous to count (TNTC). 963

Immunostainings were performed as previously described . Briefly, 5 966 um lung tissues sections were mounted on Superfrost Plus Microscope slides, 967 deparaffinized and antigen retrieval was conducted using the HIER method (Heat Induced 968 Epitope Retrieval). Subsequently, slides were stained with the primary N protein 969 monoclonal Ab 1C7 (1 µg/ml). Then slides were incubated and developed with the MACH 970

Scores of antigens were graded based on the anatomical location of viral N protein 974 staining: grade 0 = no or rare immunostaining, grade 1 = viral N protein staining only in 975 bronchi/bronchiole, grade 2 = viral N protein staining only in bronchi/bronchiole and 976 surrounding alveolar septa, grade 3 = viral N protein staining in alveolar septa distant 977 from the bronchi and bronchioles, grade 4 = viral N protein staining throughout the lung. 978

The Mann-Whitney test was used for statistical analysis. 979 980

Mouse mediastinum samples were fixed for one hour on ice in 10% NBF (Sigma) and 982 then permeabilised in PBS 1% Triton-X 100 (Sigma) for 15 min at room temperature prior 983 to staining with primary Abs for one hour at room temperature in PBS 0.5% BSA 0.5% 984

Triton. DAPI was added for the final 10 min of the 1 h incubation. After washing in PBS, 985 tissues were mounted in fluoromount G and confocal images were acquired using a Zeiss 986 LSM880 confocal laser scanning microscope. Samples were analysed using Fiji software. 987

Cluster area was delineated using IgM, and percentage area of Ki67 & CD4 staining within 988 each cluster was calculated. 989 990

Results are expressed as mean ± SEM. Where statistics are quoted, two experimental 992 groups were compared via the Student's t test or the Mann-Whitney for non-parametric significant. *, P<0.05; **, P<0.01; or ***, P<0.005 for indicated comparisons, error bars 996 represent standard error of means. 997

Intranasal vaccination with an inactivated whole influenza virus 1001 vaccine induces strong antibody responses in serum and nasal mucus of healthy adults

Estimating excess 1-year 1006 mortality associated with the COVID-19 pandemic according to underlying conditions and 1007 age: a population-based cohort study

Newcastle disease virus as a vaccine vector for 1010 humans

Recombinant newcastle disease virus expressing a foreign 1013 viral antigen is attenuated and highly immunogenic in primates

Optimization of human immunodeficiency virus gag expression by newcastle disease 1020 virus vectors for the induction of potent immune responses

The convalescent sera option for containing

Systemic and mucosal antibody responses 1028 specific to SARS-CoV-2 during mild versus severe COVID-19

Clinical and immunological features of severe and 1033 moderate coronavirus disease 2019

Severe acute 1041 respiratory syndrome coronavirus 2 detection in the female lower genital tract

Newcastle 1045 disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein 1046 of H5N1 highly pathogenic avian influenza virus protect against virus challenge in 1047 monkeys

Respiratory tract immunization of non-human primates with a Newcastle disease 1050 virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody 1051 response

Sterilizing immunity to influenza virus infection requires local antigen-specific T 1054 cell response in the lungs

Cytokine storm and COVID

Newcastle disease virus-based live 1060 attenuated vaccine completely protects chickens and mice from lethal challenge of 1061 homologous and heterologous H5N1 avian influenza viruses

Newcastle disease virus-vectored rabies vaccine is safe, highly 1065 immunogenic, and provides long-lasting protection in dogs and cats

Rapid COVID-19 vaccine development

Expression of the surface 1070 glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, 1071 a novel attenuated virus vaccine vector

Clinical features of patients infected with 2019 novel coronavirus in

Intranasal Sendai virus vaccine protects African green monkeys 1085 from infection with human parainfluenza virus-type one

Age-Related Morbidity and Mortality among Patients 1088 with COVID-19

Antitumor vaccination 1092 in patients with head and neck squamous cell carcinomas with autologous virus-modified 1093 tumor cells

Immunization of cattle with 1096 recombinant Newcastle disease virus expressing bovine herpesvirus-1

Newcastle disease virus-vectored Nipah encephalitis vaccines induce B 1102 and T cell responses in mice and long-lasting neutralizing antibodies in pigs

Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector

Multiple infections with seasonal influenza A virus induce cross-protective immunity 1109 against A(H1N1) pandemic influenza virus in a ferret model

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer 1115 treatments: a prospective cohort study

Functional assessment of cell entry and 1118 receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost

COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from

Recent progress in mucosal vaccine development: potential and 1128 limitations

Manifestations and prognosis 1131 of gastrointestinal and liver involvement in patients with COVID-19: a systematic review 1132 and meta-analysis

Newcastle disease virus-1136 infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy 1137 of resected colorectal carcinoma

Rapid in vitro assays for screening neutralizing 1140 antibodies and antivirals against SARS-CoV-2

an oncolytic virus, in patients with advanced solid cancers

A Scalable Topical Vectored Vaccine Candidate against

SARS-CoV-2. Vaccines. 8, 472

Structural and 1150 functional insights into non-structural proteins of coronaviruses

Measuring SARS-CoV-2 neutralizing antibody activity 1156 using pseudotyped and chimeric viruses

IgA 1161 dominates the early neutralizing antibody response to SARS-CoV-2

Schäfer, virus vaccine candidate

A Newcastle Disease Virus

Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2

Ad26 vaccine protects against SARS-CoV-2 1177 severe clinical disease in hamsters

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Intranasal and oral vaccination with protein-1183 based antigens: advantages, challenges and formulation strategies

Autopsy Findings and Venous 1190

Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Parenteral 1193 vaccination of mammalian livestock with Newcastle disease virus-based vector vaccines 1194 offers optimal efficacy and safety

A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in 1198 vector-immune animals

Novel avian paramyxovirus-based vaccine vectors expressing the Ebola virus 1202 glycoprotein elicit mucosal and humoral immune responses in guinea pigs

Distinct features of SARS

CoV-2-specific IgA response in COVID-19 patients

He, S. and recovery period of COVID-19 pneumonia

Noninvasive vaccination 1214 against infectious diseases

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, 1219 China: a retrospective cohort study

Immunogenicity and safety of a 1224 recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 1225 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Growth, 1228 detection, quantification, and inactivation of SARS-CoV-2

Engineered Recombinant Single Chain Variable Fragment of 1237

Monoclonal Antibody Provides Protection to Chickens Infected with H9N2 Avian 1238

Two Detailed Plaque 1240

Assay Protocols for the Quantification of Infectious SARS-CoV-2

Rapid in vitro assays for screening neutralizing 1244 antibodies and antivirals against SARS-CoV-2

Development of a real-time reverse-1248 transcription PCR for detection of Newcastle disease virus RNA in clinical samples

1251 design of prefusion-stabilized SARS-CoV-2 spikes

Measuring SARS-CoV-2 neutralizing 1260 antibody activity using pseudotyped and chimeric viruses